Isoquinolinone derivatives as nk3 antagonists

A compound according to formula I

• wherein A represents N, CH or CR1;
• each R1 independently represents hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, —C(O)—C1-6alkyl, —C(O)—C2-6alkenyl, —C(O)—C2-6alkynyl, —C(O)—O—C1-6alkyl, —C(O)—O—C2-6alkenyl, —C(O)—O—C2-6alkynyl or phenyl, wherein said phenyl, C1-6alkyl, C2-6alkenyl or C2-6alkynyl is optionally substituted with one or more substituents selected from halogen, hydroxyl, haloC1-6alkyl, nitro, C1-6alkoxy, and NR2R3;
• X represents hydrogen, C1-6alkyl optionally substituted with F, or —CRaRb—X′, wherein X′ represents a monocyclic saturated moiety having 5-6 ring atoms one of which is N and wherein one or two additional ring atom may be a hetero atom selected from N, O and S, which monocyclic ring may be substituted with one or more substituent W, wherein W is selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl or (═O);
• Ra and Rb) each individually represent hydrogen, —CH3 or halogen;
• Q represents a bond, —CH2—, —NH—, or —O—;
• Y represents C1-6alkyl, C2-6alkenyl or C2-6alkynyl, wherein said alkyl, alkenyl or alkynyl may be substituted with one or more substituents P, wherein P is selected from halogen, hydroxy, C1-6alkoxy, cyano, —S—C1-6alkyl, and a monocyclic saturated moiety having 5-6 ring atoms one ring atom of which may be N and the rest is C;
• or Y may represent a monocyclic saturated moiety having 4-6 ring atoms, wherein one of said ring atoms may be selected from N and O, the rest being C, and which monocyclic saturated moiety may be substituted with one or more substituents Z, wherein Z is selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C(O)H, —C(O)—C1-6alkyl, halogen, C1-6alkoxy, C1-6hydroxyalkyl and hydroxy;
• wherein each of R2 and R3 independently represents hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, hydroxyC1-6alkyl, or haloC1-6alkyl;
• each of R4-R8 and R9-R12 independently represents hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, halogen, NR2R3, hydroxy, cyano, nitro, C1-6alkoxy, haloC1-6alkyl or hydroxyC1-6alkyl;
• provided said compound is different from 2-methyl-1-oxo-1,2-dihydro-isoquinoline-4-carboxylic acid (1-phenyl-ethyl)-amide;
• and pharmaceutically acceptable salts thereof.